The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART: An international, phase 3, randomized controlled trial.
 
James Larkin
Honoraria - Bristol-Myers Squibb; Cancer Research UK; Eisai; GlaxoSmithKline; Gynavax; Incyte; iOnctura; Merck Serono; Novartis; Pfizer; Roche; touchEXPERTS; touchIME
Consulting or Advisory Role - Apple Tree Partners; Boston Biomedical; Bristol-Myers Squibb; Eisai; Immunocore; Incyte; iOnctura; Iovance Biotherapeutics; Merck Serono; MSD Oncology; Novartis; Pfizer; YKT Corporation
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Roche; ESMO; GlaxoSmithKline; Roche/Genentech
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Elena Frangou
No Relationships to Disclose
 
Grant Stewart
Employment - University of Cambridge
Leadership - BJU International; Natcan; National Institute for Health and Clinical Excellence
Consulting or Advisory Role - Evinova; Qurin
Research Funding - AstraZeneca (Inst)
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer
 
Ian Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); ESSA (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Johnson & Johnson/Janssen (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
(OPTIONAL) Uncompensated Relationships - ANZUP Cancer Trials Group
 
Martin Stockler
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Cristina Suárez
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche
 
Balaji Venugopal
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck; MSD Oncology; Pfizer
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer/EMD Serono
Speakers' Bureau - Bristol-Myers Squibb Foundation/Janssen; Eisai; Ipsen; Janssen Oncology; MSD Oncology; Pfizer
Research Funding - Ipsen (Inst); MSD Oncology (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - EUSA Pharma; Ipsen; Merck Serono
 
Paul Nathan
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre; ReBio; Sun Pharma
Speakers' Bureau - Bristol-Myers Squibb; Immunocore; Merck; MSD; Novartis
Research Funding - Immunocore (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Immunocore; MSD
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Telix Pharmaceuticals
Speakers' Bureau - Ipsen
Research Funding - Pfizer (Inst)
 
Craig Gedye
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Icon Cancer Care; Merck Sharp & Dohme (Inst); Novotech; SERVIER (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
David Harrison
Employment - Nucana
Leadership - ILC Therapeutics Ltd
Stock and Other Ownership Interests - ILC Therapeutics
Research Funding - Nucana
Patents, Royalties, Other Intellectual Property - Named as inventor on patent application "Cancer treatment" as David James Harrison, Mustafa Elshani: Publication date 2025/5/8 Patent office US Application number 18943650, but all rights assigned to NuCana plc. No remuneration
 
Tim Eisen
Employment - Roche
Leadership - Roche
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I); Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Roche
Other Relationship - Cambridge University Health Partners; Kidney Cancer UK; Macmillan Cancer Support; Mango Sciences
 
Toni Choueiri
Leadership - ASCO
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Faron Pharmaceuticals; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; MashupMD; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bicycle Therapeutics; Bristol-Myers Squibb; Caris Life Sciences; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - OTHER MEDICAL COMMUNICATION COMPANIES
(OPTIONAL) Uncompensated Relationships - AACR Scientific Advisory Council
 
Grisma Patel
Consulting or Advisory Role - Prokarium
Travel, Accommodations, Expenses - Prokarium
 
Sophie Merrick
No Relationships to Disclose
 
Babak Choodari - Oskooei
No Relationships to Disclose
 
Mahesh Parmar
Research Funding - AstraZeneca (Inst); Novartis (Inst)
 
Angela Meade
Research Funding - AstraZeneca (Inst)